This therapeutic strategy employs molecular glue technology to recruit TDP-43 protein aggregates to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to targeted degradation via the proteasome. This approach represents a novel mechanism for directly clearing TDP-43 pathology, which is the hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Unlike antisense oligonucleotides (ASOs) that reduce TDP-43 expression, molecular glues can selectively degrade pathological aggregated forms while preserving essential nuclear TDP-43 function.
- Primary Target: TDP-43 protein aggregates (cytoplasmic inclusions) including C-terminal fragments (CTFs, 25 kDa and 35 kDa species) and phosphorylated TDP-43 (pSer409/410) aggregates
- E3 Ligase: CRBN (cereblon) - the same target exploited by immunomodulatory imide drugs (IMiDs)
- Target Type: Molecular glue / Induced proximityducer (~400 Da)
- Expression: TDP-43 is ubiquitously expressed with high neuronal expression; pathological aggregation primarily affects motor neurons, cortical neurons, and hippocampal neurons
TDP-43 (TARDBP (TAR DNA-binding protein 43)) is a 414-amino acid RNA-binding protein that primarily localizes to the nucleus where it regulates RNA splicing, stability, and transport. In ALS and FTD-TDP, TDP-43 mislocalizes to the cytoplasm where it forms insoluble aggregates that disrupt RNA metabolism, mitochondrial function, and proteostasis. Critically, 97% of ALS cases and ~50% of FTD cases exhibit TDP-43 pathology.
Molecular glues work by simultaneously binding to a target protein and an E3 ligase, bringing them into proximity and inducing ubiquitination and subsequent proteasomal degradation of the target. The CRBN E3 ligase is particularly attractive because:
- Validated safety profile: CRBN modulators like lenalidomide and pomalidomide are FDA-approved for multiple myeloma
- Brain penetration potential: Newer CRBN modulators demonstrate improved CNS penetration
- Selective degradation: Can be engineered to preferentially target aggregated over monomeric TDP-43 due to exposed C-terminal domain in aggregates
flowchart TD
A["Normal TDP-43"] --> B["Nuclear localization"]
B --> C["RNA splicing regulation"]
C --> D["Healthy neuronal function"]
E["TDP-43 Mislocalization"] --> F["Cytoplasmic aggregation"]
F --> G["Mitochondrial dysfunction"]
F --> H["RNA metabolism disruption"]
F --> I["Proteostasis impairment"]
G --> J["Neurodegeneration"]
K["Molecular Glue"] --> LCytsolic ["T DP-43"] aggregates
L --> M["CRBN E3 Ligase Recruitment"]
M --> N["Ubiquitination"]
N --> O["Proteasomal Degradation"]
O --> P["Clearance of toxic aggregates"]
P --> Q["Preserved nuclear TDP-43 function"]
Cross-links to relevant mechanisms:
- TDP-43 Proteinopathy
- Protein Aggregation in Neurodegeneration
- Proteostasis Network
- Autophagy-Lysosomal Pathway
- TDP-43 pathology present in 97% of ALS cases (sporadic and familial)
- Motor neuron degeneration driven by toxic gain-of-function from aggregates
- Loss of nuclear TDP-43 function disrupts RNA splicing of survival genes
- Both gain-of-toxic-function and loss-of-normal-function contribute to pathogenesis
- ~50% of FTD cases have TDP-43 pathology (FTD-TDP)
- Subtypes A-D based on regional distribution of inclusions
- Cognitive and behavioral symptoms correlate with cortical involvement
- Overlap with ALS suggests common underlying mechanisms
- Progressive Supranuclear Palsy (PSP) - Some cases show TDP-43 co-pathology
- Corticobasal Degeneration (CBD) - TDP-43 present in ~50% of cases
- Alzheimer's Disease - TDP-43 pathology in ~30% of cases, correlates with cognitive decline
| Dimension |
Score |
Rationale |
| Novelty |
8/10 |
First-in-class molecular glue approach specifically for TDP-43 aggregate clearance; leverages validated CRBN platform |
| Mechanistic Rationale |
9/10 |
Strong biological basis - CRBN molecular glues have proven mechanism; direct clearance of toxic aggregates addresses root cause |
| Addresses Root Cause |
8/10 |
Directly targets and clears pathological TDP-43 aggregates; unlike ASOs, preserves essential nuclear TDP-43 function |
| Delivery Feasibility |
6/10 |
CNS delivery remains challenging; requires BBB-penetrant molecular glue design; intrathecal delivery as fallback |
| Safety Plausibility |
7/10 |
CRBN modulators have established safety profile; risk of off-target degradation requires careful compound optimization |
| Combinability |
8/10 |
Synergistic with autophagy enhancers, RNA metabolism modulators, and mitochondrial protectors |
| Biomarker Availability |
7/10 |
Phospho-TDP-43 in CSF as pharmacodynamic marker; NfL for disease progression; PET ligands in development |
| De-risking Path |
7/10 |
Cell models, mouse models, and human tissue available; CRBN modulator development provides regulatory precedent |
| Multi-disease Potential |
8/10 |
Relevant for ALS, FTD-TDP, CBD, PSP - all have TDP-43 pathology; large patient population |
| Patient Impact |
8/10 |
Disease-modifying potential; could significantly slow progression if delivered early; addresses high unmet need |
| Total |
76/100 |
|
- Design molecular glues with logP 2-4, PSA <80 Ų for optimal BBB penetration
- Incorporate polar groups to reduce P-glycoprotein efflux
- Molecular weight under 500 Da enables CNS penetration
- Intrathecal delivery: Direct CSF administration for patients with advanced disease
- AAV vector: Engineered viral delivery of gene therapy construct
- Focused ultrasound: Temporary BBB opening to enhance small molecule delivery
- Nanoemulsion formulations for improved solubility
- Lipid nanoparticle (LNP) delivery for enhanced brain penetration
- Receptor-mediated transcytosis using brain-targeting peptides
- Off-target degradation: Unintended proteins may be recruited to CRBN
- Immune modulation: CRBN is involved in immune cell function
- Teratogenicity: Known risk with IMiD class compounds
- Peripheral toxicity: Effects on non-neuronal tissues
- Structure-activity relationship (SAR) optimization to minimize off-target binding
- Tissue-selective delivery to limit peripheral exposure
- Careful patient selection (exclude women of childbearing potential)
- Monitoring of immune parameters during clinical trials
- Use of next-generation CRBN modulators with improved selectivity
- Phospho-TDP-43 in CSF: Phosphorylated TDP-43 at Ser409/410 as direct marker of target engagement
- Total TDP-43 in CSF: Changes in aggregate-associated TDP-43 levels
- CRBN engagement: Measure compound binding to CRBN in peripheral blood mononuclear cells
- Neurofilament light chain (NfL): Marker of neuronal damage; should decrease with effective treatment
- Neurofilament phosphorylated heavy chain (pNfH): More specific for motor neuron injury
- YKL-40: Marker of neuroinflammation
- ALS Functional Rating Scale-Revised (ALSFRS-R): Primary clinical endpoint
- Forced vital capacity (FVC): Respiratory function monitoring
- Motor unit number estimation (MUNE): Quantifies remaining motor neurons
- Validate molecular glue candidates in iPSC-derived motor neurons from ALS patients
- Screen for compounds that selectively degrade aggregated TDP-43 vs. monomeric TDP-43
- Establish pharmacodynamic biomarkers in cellular models
- Develop TDP-43 PET ligand for target engagement imaging
- Lead optimization for brain penetration and selectivity
- IND-enabling toxicology studies in rodent and non-human primates
- Biomarker validation study in ALS/FTD patient biofluids
- Phase 1 trial design for healthy volunteers
- Phase 1/2 trial in ALS patients with biomarker enrichment
- Dose-finding with NfL and phospho-TDP-43 as surrogate endpoints
- Phase 3 registration trial with functional endpoints
- Determine therapeutic window between aggregate clearance and nuclear TDP-43 preservation
- Identify optimal degradation vs. modulation balance for functional recovery
- Assess impact on RNA splicing dysregulation in patient-derived neurons
- Evaluate combination effects with existing ASO therapies (e.g., tofersen)
| Feature |
Molecular Glue |
Antisense Oligonucleotides |
| Mechanism |
Induced degradation |
Transcriptional knockdown |
| Target |
Aggregated TDP-43 |
All TDP-43 mRNA |
| Nuclear function |
Preserved |
Reduced |
| Delivery |
Small molecule |
Intrathecal |
| Dosing frequency |
Daily/weekly oral |
Monthly intrathecal |
| Safety focus |
Off-target degradation |
Neuroinflammation |
Molecular glues offer advantages over ASOs by selectively targeting the pathological aggregated form while preserving essential nuclear TDP-43 function. This addresses a key limitation of ASO approaches, which reduce both pathological and functional TDP-43.
- Activities: Compound library screening, hit validation, SAR optimization
- Deliverables: 3-5 lead candidates with in vitro efficacy
- Cost estimate: $2-3 million
- Activities: IND-enabling studies, formulation development, biomarker validation
- Deliverables: IND package, Phase 1-ready compound
- Cost estimate: $8-12 million
- Activities: Phase 1-3 clinical trials
- Deliverables: FDA approval or pivotal trial data
- Cost estimate: $50-100 million
- Establish academic partnership with leading ALS/FTD research centers for patient-derived cell models
- Initiate medicinal chemistry campaign focusing on CRBN-binding affinity and TDP-43 aggregate selectivity
- Develop companion biomarker assay for phospho-TDP-43 in CSF
- Engage FDA through pre-IND meeting to align on regulatory pathway
- Explore biomarker-enriched trial design using baseline NfL levels for patient stratification
- TDP-43 Proteinopathy - Background on TDP-43 pathology
- ALS Treatment Strategies - Overview of therapeutic approaches
- Tofersen - ASO therapy for SOD1-ALS (comparator)
- Autophagy-Lysosomal Pathway - Complementary clearance mechanism
- CRBN E3 Ligase Modulation - Molecular glue platform